Aratana Therapeutics, a Kansas City, KS-based biopharmaceutical company developing innovative medicines for cats and dogs, closed a $12m Series C financing.
Backers include unnamed existing and new investors.
The company intends to use the proceeds for the continued expansion of its pipeline of products.
Led by Steven St. Peter , M.D., President and Chief Executive Officer, Aratana Therapeutics has worldwide rights to the animal health applications of three new patent-protected compounds, two acquired from RaQualia Pharma Inc. and one from Pacira Pharmaceuticals, Inc., and is working to develop these compounds to address osteoarthritis-related pain, inappetence and frailty, and post-surgical pain.
FinSMEs
31/01/2013